CN114748608A - Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof - Google Patents
Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof Download PDFInfo
- Publication number
- CN114748608A CN114748608A CN202011563439.7A CN202011563439A CN114748608A CN 114748608 A CN114748608 A CN 114748608A CN 202011563439 A CN202011563439 A CN 202011563439A CN 114748608 A CN114748608 A CN 114748608A
- Authority
- CN
- China
- Prior art keywords
- helicobacter pylori
- chewing gum
- bead
- sugar
- pill
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940037467 helicobacter pylori Drugs 0.000 title claims abstract description 58
- 241000590002 Helicobacter pylori Species 0.000 title claims abstract description 57
- 239000006187 pill Substances 0.000 title claims abstract description 44
- 229940112822 chewing gum Drugs 0.000 title claims abstract description 40
- 235000015218 chewing gum Nutrition 0.000 title claims abstract description 40
- 210000000214 mouth Anatomy 0.000 title claims abstract description 34
- 239000011324 bead Substances 0.000 title claims abstract description 33
- 238000004880 explosion Methods 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 37
- 108010010803 Gelatin Proteins 0.000 claims abstract description 17
- 239000008273 gelatin Substances 0.000 claims abstract description 17
- 229920000159 gelatin Polymers 0.000 claims abstract description 17
- 235000019322 gelatine Nutrition 0.000 claims abstract description 17
- 235000011852 gelatine desserts Nutrition 0.000 claims abstract description 17
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 17
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 17
- 239000006041 probiotic Substances 0.000 claims abstract description 15
- 235000018291 probiotics Nutrition 0.000 claims abstract description 15
- 102000014171 Milk Proteins Human genes 0.000 claims abstract description 12
- 108010011756 Milk Proteins Proteins 0.000 claims abstract description 12
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 11
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229940041616 menthol Drugs 0.000 claims abstract description 11
- 239000003765 sweetening agent Substances 0.000 claims abstract description 11
- 235000020247 cow milk Nutrition 0.000 claims abstract description 7
- 235000003599 food sweetener Nutrition 0.000 claims abstract description 7
- 239000008157 edible vegetable oil Substances 0.000 claims abstract description 5
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 15
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 14
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 14
- 235000011477 liquorice Nutrition 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 12
- 239000011162 core material Substances 0.000 claims description 11
- 241000894006 Bacteria Species 0.000 claims description 9
- 235000000346 sugar Nutrition 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 238000004140 cleaning Methods 0.000 claims description 6
- 235000021239 milk protein Nutrition 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 5
- 229940001882 lactobacillus reuteri Drugs 0.000 claims description 5
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 5
- 239000008158 vegetable oil Substances 0.000 claims description 5
- 239000000811 xylitol Substances 0.000 claims description 5
- 235000010447 xylitol Nutrition 0.000 claims description 5
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 5
- 229960002675 xylitol Drugs 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 235000021551 crystal sugar Nutrition 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000021092 sugar substitutes Nutrition 0.000 claims description 4
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 3
- 239000004376 Sucralose Substances 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 235000019408 sucralose Nutrition 0.000 claims description 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 2
- 108010011485 Aspartame Proteins 0.000 claims description 2
- 241001134770 Bifidobacterium animalis Species 0.000 claims description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 2
- 239000004384 Neotame Substances 0.000 claims description 2
- 239000000605 aspartame Substances 0.000 claims description 2
- 235000010357 aspartame Nutrition 0.000 claims description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 2
- 229960003438 aspartame Drugs 0.000 claims description 2
- 229940118852 bifidobacterium animalis Drugs 0.000 claims description 2
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000019412 neotame Nutrition 0.000 claims description 2
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 2
- 108010070257 neotame Proteins 0.000 claims description 2
- 230000000529 probiotic effect Effects 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 244000269722 Thea sinensis Species 0.000 claims 2
- 239000000796 flavoring agent Substances 0.000 claims 2
- 235000019634 flavors Nutrition 0.000 claims 2
- 235000019534 high fructose corn syrup Nutrition 0.000 claims 1
- 239000008188 pellet Substances 0.000 claims 1
- 206010006326 Breath odour Diseases 0.000 abstract description 22
- 208000032139 Halitosis Diseases 0.000 abstract description 21
- 241001122767 Theaceae Species 0.000 abstract description 18
- 230000002147 killing effect Effects 0.000 abstract description 8
- 244000052616 bacterial pathogen Species 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000005540 biological transmission Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 15
- 238000005422 blasting Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000003385 bacteriostatic effect Effects 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 230000001603 reducing effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 206010017758 gastric cancer Diseases 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 201000011549 stomach cancer Diseases 0.000 description 4
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000004407 Lactalbumin Human genes 0.000 description 3
- 108090000942 Lactalbumin Proteins 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 3
- 235000021240 caseins Nutrition 0.000 description 3
- 230000001055 chewing effect Effects 0.000 description 3
- 208000002925 dental caries Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- CITFYDYEWQIEPX-UHFFFAOYSA-N Flavanol Natural products O1C2=CC(OCC=C(C)C)=CC(O)=C2C(=O)C(O)C1C1=CC=C(O)C=C1 CITFYDYEWQIEPX-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940124350 antibacterial drug Drugs 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000007334 copolymerization reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000011987 flavanols Nutrition 0.000 description 2
- 210000004211 gastric acid Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 239000001685 glycyrrhizic acid Substances 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229930003658 monoterpene Natural products 0.000 description 2
- 235000002577 monoterpenes Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
- LSHVYAFMTMFKBA-TZIWHRDSSA-N (-)-epicatechin-3-O-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=CC=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 LSHVYAFMTMFKBA-TZIWHRDSSA-N 0.000 description 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- OEIJRRGCTVHYTH-UHFFFAOYSA-N Favan-3-ol Chemical compound OC1CC2=CC=CC=C2OC1C1=CC=CC=C1 OEIJRRGCTVHYTH-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001278898 Glycyrrhiza inflata Species 0.000 description 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 description 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000015710 Iron-Deficiency Anemia Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 229930194248 Licoflavone Natural products 0.000 description 1
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007117 Oral Ulcer Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010039088 Rhinitis atrophic Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000002814 agar dilution Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000001013 cariogenic effect Effects 0.000 description 1
- 229940021722 caseins Drugs 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 229950001002 cianidanol Drugs 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000000701 coagulant Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- -1 cyclic monoterpenes Chemical class 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000002206 flavan-3-ols Chemical class 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- HVQAJTFOCKOKIN-UHFFFAOYSA-N flavonol Natural products O1C2=CC=CC=C2C(=O)C(O)=C1C1=CC=CC=C1 HVQAJTFOCKOKIN-UHFFFAOYSA-N 0.000 description 1
- 150000002216 flavonol derivatives Chemical class 0.000 description 1
- 235000011957 flavonols Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003132 food thickener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- 229960001625 furazolidone Drugs 0.000 description 1
- PLHJDBGFXBMTGZ-WEVVVXLNSA-N furazolidone Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)OCC1 PLHJDBGFXBMTGZ-WEVVVXLNSA-N 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- DLINORNFHVEIFE-UHFFFAOYSA-N hydrogen peroxide;zinc Chemical compound [Zn].OO DLINORNFHVEIFE-UHFFFAOYSA-N 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000009048 phenolic acids Nutrition 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Confectionery (AREA)
Abstract
The invention discloses a bead chewing gum pill for resisting oral helicobacter pylori explosion, which is prepared from (by weight parts) Glycyrrhrizae radix 0.1-2.5; 0.01-1.0% of tea polyphenol; 1.0-20.0% of probiotics; 0.1-5.0 parts of cow milk protein; 0.5-8.0% of menthol; 0.1-0.5% of a sweetening agent; 6-8 parts of gelatin; 0.5-2% of glycerol; edible vegetable oil, adding to 100 weight parts. The chewing gum pill of the invention applies the principle of cutting off the oral transmission path of helicobacter pylori, has the advantages of quickly eliminating halitosis, inhibiting and killing oral HP and pathogenic bacteria, maintaining normal micro-ecology of oral cavity and the like, and can be used by various people. In addition, the invention also discloses a preparation method of the chewing gum pills.
Description
Technical Field
The invention relates to a chewing gum, in particular to a bead chewing gum pill for resisting helicobacter pylori explosion in oral cavity; in addition, the invention also relates to a preparation method of the bead chewing gum pill for resisting the helicobacter pylori explosion of the oral cavity.
Background
Helicobacter Pylori (HP) is defined as an infectious disease that is transmitted orally, and HP in the stomach has a close relationship with HP in the oral cavity. 70-80% of gastric ulcer and 95% of duodenal ulcer are related to the gastric ulcer, and the risk of gastric cancer can be increased by 4-6 times. As a first carcinogenic source of human gastric cancer, the human gastric cancer is listed by the world health organization as early as 1994 and is an important pathogenic factor of diseases such as chronic gastritis, peptic ulcer, gastric cancer and the like. It is also associated with diseases of other systems outside the gastrointestinal tract, such as iron deficiency anemia, skin diseases, idiopathic thrombocytopenic purpura, coronary heart disease, hypertension, halitosis, oral ulcer, periodontitis, etc. Data from the american microbiology society, journal of clinical microbiology, 2010, show HP infection in about half of the world population. In China, according to epidemiological investigation of the Chinese medical society, the average HP infection rate is higher in China, and is about 59%. This figure is much higher than hepatitis b (8%) and tuberculosis (0.5%. 2010, department of health data). Kyoto viral consensus on Helicobacter pylori university in 2014 suggested that the major period of HP infection was acquired by an intra-family translocation route in childhood (under 12 years, developed countries). Therefore, measures such as keeping good personal life and hygiene habits, washing hands in time, avoiding meals, keeping oral hygiene and the like are measures for reducing the infection rate.
Helicobacter pylori propagates from human to human via the mouth-to-mouth, stomach-to-mouth and/or feces-to-mouth routes. The fecal-oral route mainly occurs in countries/regions with poor hygienic and economic conditions, while oral-oral transmission is probably the most important route in our country. Currently, only the removal of HP in the stomach is considered in the clinical treatment of digestive system diseases, and the infection and the spread control of HP in the oral cavity are ignored. HP radical treatment mostly adopts triple or quadruple therapy, and antibacterial drugs must be used according to the prescriptions, sufficient quantities and specifications. The disadvantages are that: the application of a large amount of antibacterial drugs increases the drug resistance rate and drug resistance of HP.
The chewing gum is particularly popular with young people, has the functions of keeping the faint scent of the oral cavity and exercising facial muscles, but can reflexively secrete a large amount of gastric acid after being chewed for a long time, and the symptoms are aggravated particularly for people with stomach diseases. The existing upgraded bead-popping chewing gum pill can be chewed in a buccal manner and also can be directly swallowed, so that fresh and tasteless breath can be realized, and the defect that the residues are very difficult to clear due to strong viscosity of the traditional chewing gum matrix is avoided.
Disclosure of Invention
According to the embodiment, the invention aims to provide the bead chewing pill for resisting the helicobacter pylori explosion in the oral cavity, which can quickly eliminate halitosis, keep the oral cavity fresh for a long time, kill oral HP and pathogenic bacteria and keep the normal micro-ecology in the oral cavity; in addition, the invention also provides a preparation method of the bead chewing gum pill for resisting the helicobacter pylori explosion of the oral cavity.
According to the embodiment, the invention provides an anti-oral helicobacter pylori bead chewing gum pill which is composed of the following components in parts by weight:
0.1 to 2.5 portions of liquorice;
0.01-1 of tea polyphenol;
1-20 parts of probiotics;
0.1-5 of cow milk protein;
0.5-8 parts of menthol;
0.1-0.5 of sweetening agent;
6-8 parts of gelatin;
0.5-2 parts of glycerol;
edible vegetable oil, adding to 100 weight parts.
According to the embodiment, the preparation method of the bead chewing gum pill for resisting the helicobacter pylori explosion in the oral cavity comprises the following steps:
(1) preparing an external coating wall material: weighing glycerol and gelatin, placing the glycerol and the gelatin into a preparation kettle at 30-45 ℃, uniformly stirring, measuring the effective viscosity of 1000-1550cp, and standing for later use;
(2) preparing a core material: weighing liquorice, tea polyphenol, milk protein, menthol and a sweetening agent, uniformly mixing, and adding probiotics as a core material;
(3) respectively introducing the prepared wall material and core material into a dripping pill machine, dripping the wall material and the core material into edible vegetable oil at 30-45 deg.C, shrinking by concentric multi-layer drippers under the action of surface tension to obtain dripping pills, cooling and cleaning with purified water to obtain wet pills;
(4) drying the wet pills to obtain dry exploded beads, cleaning the dried exploded beads with edible ethanol to remove vegetable oil and damaged exploded beads attached to the surfaces, and air-drying to obtain the oral cavity helicobacter pylori explosion-resistant bead chewing gum pills with the water content of 8-12%.
The invention relates to liquorice and a traditional Chinese medicine name. Is dried root and rhizome of Glycyrrhiza uralensis Fisch, Glycyrrhiza inflata Bat, or Glycyrrhiza glabra L. Distributed in northeast, northeast China, Shaanxi, Gansu, Qinghai, Xinjiang, Shandong, etc. Has the effects of invigorating spleen and replenishing qi, clearing away heat and toxic materials, eliminating phlegm and stopping cough, relieving spasm and pain, and harmonizing the medicines. It is indicated for spleen and stomach deficiency, lassitude and hypodynamia, palpitation and shortness of breath, cough with profuse sputum, spasm and pain of abdomen and limbs, carbuncle and sore, and to relieve toxicity and strong action of drugs. In recent years, the discovery has remarkable activities of resisting inflammation, hepatitis B virus, AIDS virus and the like and maintaining the immune balance of organisms, and the main pharmacological components of the composition have the antibacterial effect of glycyrrhizic acid and licoflavone on Hp, which is equivalent to the effect of inhibiting and killing Hp by common antibiotics such as clarithromycin, amoxicillin, furazolidone and the like.
The tea polyphenol is a tea extract, and has the following English name: tea Polyphenols; and the name is as follows: tea tannin, chemical formula C17H19N3O, molecular weight 281.36. Tea polyphenol is the main component forming the color, aroma and taste of tea and is the main component of tea with health care function. Tea polyphenol is the general term of polyphenol substances in tea, and comprises flavanols, anthocyanins, flavonoids, flavonols, phenolic acids and the like, wherein the flavanol catechin is the most important substance. The tea polyphenols can inhibit calcium reduction of human body, effectively prevent dental caries, and has effects of protecting and consolidating teeth. Meanwhile, the components such as vitamin C in the tea can reduce the turbidity of eye crystals and has the effects of reducing eye diseases and protecting eyes and improving eyesight. The tea polyphenols have effects of removing toxic substance and resisting radiation, and can effectively prevent radioactive substance from invading and rapidly discharge out of body. The tea polyphenol in the invention mainly plays roles in maintaining normal ecology of oral cavity, protecting teeth and preventing decayed teeth.
The probiotics comprise one or more of lactobacillus reuteri, lactobacillus acidophilus, bifidobacterium animalis, bifidobacterium lactis and lactobacillus rhamnosus; further preferred is the case. Lactobacillus reuteri is a broad-spectrum effective antibacterial substance, and can inhibit the growth of Escherichia, Salmonella, Shigella, Listeria, Vibrio, Clostridium, and Staphylococcus. Research shows that the concentration of the Roisella is 15-30 mu g/ml, the Roisella can inhibit the growth of gram-positive bacteria, gram-negative bacteria, yeast, fungi and protozoa, is harmless to human and animals, and has wide potential application in the aspects of biological bacteriostat, anti-infection therapeutic agent, biological cross-linking agent, precursor of novel biological materials and the like. Roiximab can be used as chewing gum additive for killing pathogenic bacteria of Hp in oral cavity, preventing dental caries, and relieving halitosis. The lactobacillus has obvious inhibition on oral pathogens and has inhibition on halitosis-related bacteria; the bifidobacterium is used as a physiological beneficial bacterium, and has various important physiological functions of biological barrier, nutrition, anti-tumor, immunity enhancement, gastrointestinal tract function improvement, aging resistance and the like on human health.
The cow milk protein is a general term for a plurality of protein mixtures in cow milk. Mainly comprises two parts of casein (casein) and lactalbumin (lacto-bumin). The former is protein precipitated from milk at 20 deg.C and pH 4.6, and the rest of the protein dissolved in whey is called whey protein. The lactalbumin comprises beta-lactoglobulin, alpha-lactalbumin, serum albumin, immunoglobulin and other trace proteins, such as copper, zinc-superoxide dismutase, etc. All caseins and whey proteins are products of milk secretory cell synthesis in the mammary gland, except for serum albumin, immunoglobulins from blood. The milk protein is rich in cysteine and methionine, can maintain the level of antioxidants in a human body, and is an essential substance indispensable to life activities of growth, development, aging resistance and the like of the human body.
The edible Gelatin (Gelatin) is a hydrolysate of collagen, is a high protein without fat, does not contain cholesterol, and is a natural nutritional food thickener. After eating, people can not become fat, and the physical strength can not be reduced. Gelatin is also a strong protective colloid, has strong emulsifying power, and can inhibit coagulation of proteins such as milk and soybean milk due to gastric acid after entering stomach, thereby facilitating digestion of food. Gelatin is a macromolecular hydrocolloid, which is the product of partial hydrolysis of collagen. When edible gelatin is used as a coagulant, the bonding strength is mainly required.
The sweetening agent is one or more of sugar substitute, sugar, glucose syrup, high fructose syrup and the like. The sugar substitute is one or more of xylitol, sucralose, neotame, aspartame and acesulfame potassium; the edible sugar is one or more of white sugar, soft white sugar, yellow granulated sugar, brown granulated sugar, polycrystal crystal sugar, monocrystal crystal sugar, cubic sugar and borneose.
The menthol has mint fragrance and a cooling effect, and is commonly used as an aromatizer for toothpaste, perfume, beverage, candy and the like. Menthol is the main component of peppermint oil, is one of cyclic monoterpenes, is a high-volatility essential oil produced by plants, mainly contains hemiterpenes, monoterpenes and sesquiterpenes, has the effects of relieving itching, relieving pain, preventing corrosion, stimulating, anaesthetizing, cooling and resisting inflammation, and can be used for treating headache, neuralgia, pruritus, respiratory inflammation, atrophic rhinitis, hoarseness and the like.
Other raw materials in the invention are common raw materials in the prior art.
In the formula of the oral cavity helicobacter pylori resistant bead-blasting oral cavity fragrant pills, the liquorice and the tea polyphenol are bactericides and have the functions of inhibiting and killing HP and pathogenic bacteria. The probiotics and lactoferrin have the functions of resisting cancer, resisting microorganisms and oxidation and improving immunity. Xylitol, menthol, glycerol and the like are common raw materials in the prior chewing gum production and have the function of regulating the mouthfeel. As a result of the comprehensive effects of the components, the bead-blasting chewing gum has the functions of killing oral HP and other pathogenic microorganisms, keeping the oral cavity fresh and relieving halitosis.
The invention applies the principle of monarch, minister, assistant and guide of the traditional Chinese medicine, takes the traditional Chinese medicine plants with the continuous sterilization function as monarch drugs, takes the probiotics and the milk protein as minister drugs, and combines with the novel form of the bead-blasting chewing gum pills, makes full use of the buccal or chewing action in the oral cavity, leads the effective components to be rapidly absorbed by the human body through the oral mucosa and the blood brain barrier, thereby achieving the characteristics of restoring the normal micro-ecology of the oral cavity and killing the oral HP. Meanwhile, probiotic strains capable of accurately identifying HP are applied, and are attached to the surface of HP to form a copolymerization bacterial body by utilizing the principle of bacterium preparation by bacteria, and the copolymerization bacterial body falls off from the surface of the oral cavity and is discharged out of the human body during tooth brushing, so that the effect of reducing and controlling the quantity of HP in the oral cavity is achieved. The application of the probiotics can not cause HP to generate drug resistance, can widely inhibit the propagation and growth of gram-positive bacteria, gram-negative bacteria, yeast, fungi and the like, and antagonize the colonization of harmful bacteria such as HP and the like, thereby improving the oral flora distribution and restoring the normal micro-ecology of the oral cavity.
The bead-shaped chewing gum pill for resisting the oral cavity helicobacter pylori explosion has the advantages of quickly eliminating halitosis, keeping the oral cavity fresh for a long time, killing oral cavity HP and pathogenic bacteria, maintaining normal micro-ecology of the oral cavity and the like.
The bead chewing gum pill for resisting the oral cavity helicobacter pylori explosion has the following advantages:
1. the Chinese old liquorice is refined, and the glycyrrhizic acid, the flavone and other antioxidant substances have the characteristics of removing free radicals and natural bacteriostasis, replace clinical antibiotics and avoid the occurrence of antibiotic resistance.
2. The liquorice, the tea polyphenol, the probiotics and the milk protein can defend and tonify primordial qi of human bodies, such as heart qi, stomach qi, spleen qi and the like, improve the immunity and promote the health and micro-ecology of the human bodies.
3. The oral liquid passes through blood brain barrier through mucosa, has good absorption effect, has good inhibition and killing effect on oral cavity HP, and has obvious effect of relieving HP bacteria-derived halitosis.
4. Can effectively inhibit and remove dental plaque, reduce bacterial adhesion and aggregation, kill cariogenic bacteria, and prevent dental caries.
5. The chewing gum can keep fresh breath, can be chewed and swallowed, has no residue after chewing, and can keep the oral cavity fresh for a long time.
6. Is convenient to take and can be taken by various people.
Drawings
FIG. 1 shows 1: 2; 1: 4; the three concentration plates 1:8 all grow in a sterile manner and have bacteriostatic effects.
Detailed Description
The invention is further illustrated with reference to the following figures and specific examples. These examples are to be construed as merely illustrative and not limitative of the remainder of the disclosure in any way whatsoever. After reading the description of the invention, one skilled in the art can make various changes and modifications to the invention, and such equivalent changes and modifications also fall into the scope of the invention defined by the claims.
Example 1: preparation of bead-shaped chewing gum pill for resisting helicobacter pylori explosion in oral cavity
Weighing 20 kg of liquorice, 5 kg of tea polyphenol, 15 kg of probiotics (lactobacillus reuteri, lactobacillus acidophilus and animal bifidobacteria), 5 kg of cow milk protein, 10 kg of menthol, 3 kg of xylitol, 75 kg of gelatin, 15 kg of glycerol and 852 kg of vegetable oil.
In this embodiment, the wall material includes purified water, gelatin and glycerin, and the weight ratio is 2.0: 1.0: 0.5; the weight of the wall material accounts for 8-10% of the total weight of the bead-popping chewing gum. The preparation process comprises the following steps:
(1) adding purified water, glycerol, gelatin, etc. into a preparation kettle, heating to 30-45 deg.C, stirring uniformly for 45min, standing, and finishing preparation of external wall material;
(2) uniformly mixing raw materials such as liquorice, tea extracts, milk protein, menthol, xylitol and the like, and preparing a core material by probiotics:
(3) respectively introducing the prepared wall material and core material into a dripping pill machine at 30-45 deg.C, respectively introducing the wall material and core material into independent channels of concentric multi-layer drippers to obtain dripping pills, filtering, cleaning with purified water, and making into wet pills.
(4) Drying the wet pill to obtain dried blasting bead, cleaning with edible ethanol to remove vegetable oil and damaged blasting bead attached on surface, and air drying to obtain final product (water content: 8% -12%).
Example 2: preparation of bead-shaped chewing gum pill for resisting helicobacter pylori explosion in oral cavity
Weighing 1 kg of liquorice, 1 kg of tea polyphenol, 5 kg of probiotics (lactobacillus reuteri), 2 kg of cow milk protein, 1.4 kg of menthol, 0.1 kg of sucralose, 7.1 kg of gelatin, 0.9 kg of glycerol and 81.5 kg of vegetable oil for later use.
In this embodiment, the wall material includes water, gelatin and glycerin, and the weight ratio is 2.0: 1.0: 0.5; the weight of the wall material accounts for 8-10% of the total weight of the bead-popping chewing gum.
The preparation method is the same as example 1.
Test example 1
The anti-oral helicobacter pylori bead chewing gum pill prepared in the embodiment 1 of the invention is used for carrying out bacteriostasis tests. The specific test examples are as follows:
1. basis of experiment
According to the technical requirement of WS/T639-2018 antimicrobial drug sensitivity test of 4.2.1 agar dilution method, the bacteriostatic test is carried out.
2. Test method
2.1 preparing a helicobacter pylori culture medium with the concentration of 2 times, sterilizing and storing in an environment with the temperature of 55 ℃ for later use.
2.2 the anti-oral helicobacter pylori blasting bead chewing gum pill prepared in the example 1 contains 3000g of sample content of 2 percent of liquorice and is diluted in a gradient way according to the laboratory requirement, and the ratio is 1: 2; 1: 4; 1:8 for standby.
2.3 mixing the sample with culture medium at a ratio of 1:1, adding sterile defibrinated goat blood and helicobacter pylori additive, pouring into a flat plate, and solidifying for use.
2.4 the diluted bacterial suspension was inoculated onto a sample plate using a disposable 1. mu.L inoculating loop, 3. mu.L each, three sites in total, and the plate was left to dry at room temperature until the bacterial spot was dried. Continuously culturing for 5 days, and observing the growth condition of the lawn.
3. Evaluation of bacteriostatic Effect
And observing the growth condition of the colony at the inoculation point of the plate by naked eyes. If the bacteria-free colony grows, the concentration sample has the bacteriostatic action on the helicobacter pylori.
4. Test results
As shown in fig. 1, the experiment was designed for 1: 2; 1: 4; the three concentration plates 1:8 all grow in a sterile manner, namely, the three concentrations in the experimental design have the bacteriostatic effect.
3000g of sample contents containing 2% of liquorice in the anti-oral helicobacter pylori blasting bead chewing gum pills prepared in the example 2 are subjected to gradient dilution according to the laboratory requirements, and the ratio is 1: 2; 1: 4; 1:8, and carrying out the bacteriostasis test. The test results also show that 1: 2; 1: 4; the three concentration plates of 1:8 have bacteriostatic effects when all three concentrations of the bacteria-free colonies grow.
Test example 2
The anti-oral helicobacter pylori bead chewing gum pill prepared in the embodiment 2 of the invention is used for carrying out the test of relieving halitosis. The specific test examples are as follows:
1. evaluation method
The halitosis index is as follows: the measurements were performed by effective analytical instrumentation (breath gauge Halimeter Blu) using the main odor causing factor.
2. And (4) judging the standard:
after the statistical engineer calculates that 14 days later than the test product (anti-oral helicobacter pylori bead chewing gum) prepared in the example 2, the test group subjects take or chew 6g-12g per time 2-4 times per day, the halitosis index value after use is obviously lower than the value of the self baseline, and the difference between the halitosis index value of the test group subjects and the self baseline is obviously larger than the difference between the halitosis index value of the control group (only using placebo) after 14 days and the self baseline, and the anti-oral helicobacter pylori bead chewing gum is considered to have the effect of relieving halitosis.
Placebo is a chewing gum without active ingredients that reduce oral malodor.
3. Evaluation results
3.1 Point-to-Point comparison of time points
Note: mean (± standard error) rate of decline compared to baseline.
Note: the significance labeling method comprises the following steps: "n.s." means no statistical difference, p > 0.05; ". indicates there was a very significant difference, p > 0.05.
3.2 comparison of halitosis indicators between products
Note: mean value (± standard error)
Note: the significance labeling method comprises the following steps: "n.s." means no statistical difference p > 0.05; ". indicates significant differences, p > 0.05.
4. Conclusion of evaluation
Through clinical tests, 33 people in the test group use the test product (anti-helicobacter pylori blasting bead chewing gum pill) and test subjects in the test group take or chew 6g-12g pills each time according to 2-4 times per day. Compared with the baseline, the halitosis index of the subject after 14 days has significant difference, and the halitosis reducing effect is obvious. While the control group used only placebo, there was no significant difference between the bad breath indicator and the basal value in the subjects after 14 days.
The anti-oral helicobacter pylori bead chewing gum pill prepared in the embodiment 1 of the invention is used for carrying out the halitosis reducing test, and the test result also shows that the halitosis indexes of the subjects after 14 days are obviously different from the baseline, and the halitosis reducing effect is obvious.
The test results prove that: the anti-oral helicobacter pylori bead-bursting chewing gum pill has the effect of obviously relieving halitosis.
Claims (5)
1. The bead chewing gum pill for resisting oral helicobacter pylori explosion is characterized by comprising the following components in parts by weight:
0.1 to 2.5 portions of liquorice;
0.01-1 of tea polyphenol;
1-20 parts of probiotics;
0.1-5 of cow milk protein;
0.5-8 parts of menthol;
0.1-0.5 of sweetening agent;
6-8 parts of gelatin;
0.5-2 parts of glycerol;
edible vegetable oil added to 100 weight portions.
2. The anti-oral-cavity helicobacter pylori popping bead flavor pill as claimed in claim 1, wherein the probiotic bacteria are selected from the group consisting of lactobacillus reuteri, lactobacillus acidophilus, bifidobacterium animalis, bifidobacterium lactis and lactobacillus rhamnosus.
3. The anti-oral helicobacter pylori popping bead chewing gum pellet as claimed in claim 1, wherein the sweetener is selected from the group consisting of sugar substitutes, sugar, glucose syrup and glucose-fructose syrup.
4. The anti-oral helicobacter pylori popping bead flavor pill as claimed in claim 3, wherein the sugar substitute is selected from the group consisting of xylitol, sucralose, neotame, aspartame and acesulfame k; the sugar is selected from white sugar, soft sugar, yellow sugar, brown sugar, polycrystal crystal sugar, monocrystal crystal sugar, cubic sugar and borneose.
5. A preparation method of a bead chewing gum pill for resisting oral helicobacter pylori explosion is characterized by comprising the following steps:
(1) preparing an external coating wall material: weighing glycerol and gelatin, placing the glycerol and the gelatin into a preparation kettle at 30-45 ℃, uniformly stirring, measuring the effective viscosity of 1000-1550cp, and standing for later use;
(2) preparing a core material: weighing liquorice, tea polyphenol, milk protein, menthol and a sweetening agent, uniformly mixing, and adding probiotics as a core material;
(3) respectively introducing the prepared wall material and core material into a dripping pill machine, dripping the wall material and the core material into edible vegetable oil at 30-45 deg.C, shrinking by concentric multi-layer drippers under the action of surface tension to obtain dripping pills, cooling and cleaning with purified water to obtain wet pills;
(4) drying the wet pills to obtain dry exploded beads, cleaning the dried exploded beads with edible ethanol to remove vegetable oil and damaged exploded beads attached to the surfaces, and air-drying to obtain the oral cavity helicobacter pylori explosion-resistant bead chewing gum pills with the water content of 8-12%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011563439.7A CN114748608A (en) | 2020-12-25 | 2020-12-25 | Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011563439.7A CN114748608A (en) | 2020-12-25 | 2020-12-25 | Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114748608A true CN114748608A (en) | 2022-07-15 |
Family
ID=82324467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011563439.7A Pending CN114748608A (en) | 2020-12-25 | 2020-12-25 | Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114748608A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487109A (en) * | 2022-09-21 | 2022-12-20 | 上海利康精准医疗技术有限公司 | Bead-blasting chewing gum pill with function of inhibiting helicobacter pylori and preparation method thereof |
CN116492285A (en) * | 2023-06-29 | 2023-07-28 | 深圳市波尔顿科技有限公司 | Composite probiotic composition for oral cavity, application and product thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202009011379U1 (en) * | 2009-08-24 | 2010-12-30 | Khalifa, Samir | Oral preparations for oral and dental care and combating halitosis |
CN103892028A (en) * | 2014-04-24 | 2014-07-02 | 上海利康消毒高科技有限公司 | Chewing gum capable of resisting oral helicobacter pylori, and preparation method thereof |
CN105685342A (en) * | 2016-02-18 | 2016-06-22 | 江苏微康生物科技有限公司 | Probiotic buccal tablet and preparation method thereof |
CN109717289A (en) * | 2019-01-31 | 2019-05-07 | 安徽仙奇生物工程技术有限公司 | A kind of quick-fried pearl chewing gum and preparation method thereof |
-
2020
- 2020-12-25 CN CN202011563439.7A patent/CN114748608A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE202009011379U1 (en) * | 2009-08-24 | 2010-12-30 | Khalifa, Samir | Oral preparations for oral and dental care and combating halitosis |
CN103892028A (en) * | 2014-04-24 | 2014-07-02 | 上海利康消毒高科技有限公司 | Chewing gum capable of resisting oral helicobacter pylori, and preparation method thereof |
CN105685342A (en) * | 2016-02-18 | 2016-06-22 | 江苏微康生物科技有限公司 | Probiotic buccal tablet and preparation method thereof |
CN109717289A (en) * | 2019-01-31 | 2019-05-07 | 安徽仙奇生物工程技术有限公司 | A kind of quick-fried pearl chewing gum and preparation method thereof |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115487109A (en) * | 2022-09-21 | 2022-12-20 | 上海利康精准医疗技术有限公司 | Bead-blasting chewing gum pill with function of inhibiting helicobacter pylori and preparation method thereof |
CN115487109B (en) * | 2022-09-21 | 2024-02-27 | 上海利康精准医疗技术有限公司 | Bead-explosion fragrant pill with helicobacter pylori inhibiting function and preparation method thereof |
CN116492285A (en) * | 2023-06-29 | 2023-07-28 | 深圳市波尔顿科技有限公司 | Composite probiotic composition for oral cavity, application and product thereof |
CN116492285B (en) * | 2023-06-29 | 2023-09-22 | 深圳市波尔顿科技有限公司 | Composite probiotic composition for oral cavity, application and product thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI463986B (en) | New use of lactobacillus plantarum cmu995 strain | |
CN110051003A (en) | A kind of compound probiotic composition and its application | |
BR112013003761B1 (en) | COMPOSITION, PROBIOTIC PRODUCT, USE OF SUCH COMPOSITION, PHARMACEUTICAL COMPOSITION, EDIBLE PRODUCT, COSMETIC COMPOSITION, ORAL CARE PRODUCT AND USES OF LACTOBACILLUS PLANTARUM AND LACTOBACILLUS BREVIS STRINGS | |
CN114748608A (en) | Bead chewing gum pill for resisting oral cavity helicobacter pylori explosion and preparation method thereof | |
CN113577218A (en) | Inactivated probiotic traditional Chinese medicine composition for inhibiting helicobacter pylori and preparation method and application thereof | |
CN102415523A (en) | Composition containing compound functional food factor | |
JP2016513631A (en) | Lactobacillus plantarum NCC2936 preparation and oral health | |
WO2020059995A1 (en) | Health drink composition for preventing liver damage caused by alcohol while providing excellent hangover relief | |
CN111034891A (en) | Solid beverage containing probiotic composition and preparation method thereof | |
CN110384725B (en) | A Chinese medicinal composition for regulating oral flora and preparation method of active extract thereof | |
CN108714208A (en) | Composition, preparation method, using and relieve stress, improve sleep product | |
TW201902499A (en) | COMPOSITION FOR ACTIVATING Toll-LIKE RECEPTOR 2 | |
JP3998293B2 (en) | Helicobacter pylori inhibitor | |
Olabiran et al. | Quality chracterization of functional soy-based yoghurt incorporated with scent leaf (Ocimum gratissimum) essential oil microcapsules | |
JPWO2003099304A1 (en) | Anti-periodontal disease bacteria composition, anti-periodontal disease food and drink containing the anti-periodontal disease bacteria composition, and oral cleanser | |
JP2005520807A (en) | D-Tagatose as an anti-biofilm agent | |
CN103798494A (en) | Stomach invigorating and spleen benefiting black tea fungus haw jelly as well as preparation method thereof | |
KR20200017912A (en) | Antibacterial Composition for Porphyromonas Gingivalis Comprising Plant Extract or Lactic Acid Bacteria Fermentation Product thereof | |
KR20130097537A (en) | Composition comprising mixture of hot water extract of curcuma longa radix, acorus gramineus soland and polygala tenuifolia to enhance cognition and memory | |
US20040175444A1 (en) | Crude drug compositions and the process for preparing them | |
CN109619248A (en) | Quickly eliminate bad breath the sugar-free hard candy piece and preparation method thereof for removing helicobacter pylori | |
JPS63291579A (en) | Proliferation-promoting agent for bifidobacterium | |
CN115487109B (en) | Bead-explosion fragrant pill with helicobacter pylori inhibiting function and preparation method thereof | |
Buchilina | Influence of Health Beneficial Monk Fruit Sweetener on Microbial and Physicochemical Characteristics of Camel Milk Yogurt | |
WO2010119804A1 (en) | Anti-mental fatigue agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220715 |